3

Psychedelics are back.

But not in the way you might think.

We’re not talking about a throwback to the 1960s, nor are we talking about college kids experimenting acid and mushrooms for the fun of it.

This time, it’s all scientific.

New medical research is showing some very promising treatments for all kinds of mental health issues, ranging from anxiety, depression, PTSD, and addiction.

Of course, this is really what the intention was for psychedelics when they first arrived on the scene, ushered in by a number of brilliant scientists, including…

Albert Hoffman, the Swiss pharmaceutical chemist who created LSD in 1938.

Dr. Humphrey Osmand, an English psychiatrist, who actually coined the term psychedelics, which means “mind-manifesting.” in 1957,

And Dr. Timothy Leary, who started the Harvard Psilocybin Project in 1960 to study the effects of psilocybin –– the active ingredients found in magic mushrooms.

While most psychedelics are still considered federally illegal today, between1953 and the early 1970s, the federal government spent $4 million to pay for 116 studies of LSD and psilocybin involving over 1,700 subjects.

Those psychedelics were tested on people with psychedelic disorders ranging from alcoholism to schizophrenia. And the results were promising. There were even calls for more research. That is until President Richard Nixon, signed the controlled substances act in 1970 which prohibited the use, for almost any purpose, including research, of these drugs.

But a lot has changed since then.

4

And over the past few years, we’ve begun to see a real major shift in how society, the medical community, and the federal government view psychedelics.

Today, the FDA is actually clearing the way for new psychedelics research, with some companies getting fast-tracked on their clinical trials. This is a very big deal. And the research that’s now coming out of some of the most prestigious research facilities and universities in the world shows that these drugs are helping with eating disorders, OCD, and major depression, including cases that didn’t respond to traditional medicine, such as Prozac and Zoloft.

So how do these psychedelics work?

Well, think of your brain as a switchboard, where the wires have been plugged in a certain way ever since you were born. And they’ve never been refreshed...

Psychedelics changes all of that.

Psychedelics essentially disconnect all the wires and give this switchboard ( the brain), a break.

Then the wires are reconnected, but in a different order, that refreshes everything and gets it flowing again.

There has been some fascinating research on this were, after psychedelics treatments have happened, brain scans show more connectivity and integration in the brain, suggesting that maybe psychedelics work by breaking down old patterns and kickstarting the brain into new ones.

Now In this report, I have included six videos that go into detail on how psychedelics work and why the burgeoning psychedelics industry could be one of the most disruptive breakthroughs in modern mental health, offering a lot of sick people, new, effective treatments, and investors, a huge opportunity to build some serious wealth.

Check it out…

5

THE FUTURE OF PSYCHEDELIC-ASSISTED PSYCHOTHERAPY

COULD PSYCHEDELIC DRUGS BE A CURE FOR DEPRESSION?

6

THE FUTURE AND SCIENCE OF PSYCHEDELICS

THE NEW SCIENCE OF PSYCHEDELICS

7

MICRODOSING PSYCHEDELICS

HOW MDMA IS BEING USED TO TREAT PTSD

8

Green Chip Stocks © Angel Publishing 2020, 3 E Read Street, Baltimore, MD 21202. All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Green Chip Stocks and Angel Publishing do not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law.